Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Insulin Resistance the Hinge Between Hypertension and Type 2 Diabetes.

Tytuł:
Insulin Resistance the Hinge Between Hypertension and Type 2 Diabetes.
Autorzy:
Mancusi C; Department of Advanced Biomedical Sciences, Federico II University of Naples, Via S. Pansini n. 5, 80131, Naples, Italy.
Izzo R; Department of Advanced Biomedical Sciences, Federico II University of Naples, Via S. Pansini n. 5, 80131, Naples, Italy.
di Gioia G; Department of Advanced Biomedical Sciences, Federico II University of Naples, Via S. Pansini n. 5, 80131, Naples, Italy.
Losi MA; Department of Advanced Biomedical Sciences, Federico II University of Naples, Via S. Pansini n. 5, 80131, Naples, Italy.
Barbato E; Department of Advanced Biomedical Sciences, Federico II University of Naples, Via S. Pansini n. 5, 80131, Naples, Italy.
Morisco C; Department of Advanced Biomedical Sciences, Federico II University of Naples, Via S. Pansini n. 5, 80131, Naples, Italy. .
Źródło:
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension [High Blood Press Cardiovasc Prev] 2020 Dec; Vol. 27 (6), pp. 515-526. Date of Electronic Publication: 2020 Sep 22.
Typ publikacji:
Journal Article; Review
Język:
English
Imprint Name(s):
Publication: Auckland : Adis, Springer International
Original Publication: Milano : Editrice Kurtis s.r.l., c1992-
MeSH Terms:
Blood Pressure*
Insulin Resistance*
Diabetes Mellitus, Type 2/*physiopathology
Essential Hypertension/*physiopathology
Animals ; Biomarkers/blood ; Blood Glucose/metabolism ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/epidemiology ; Essential Hypertension/blood ; Essential Hypertension/epidemiology ; Humans ; Incidence ; Insulin/blood ; Prognosis ; Risk Factors ; Signal Transduction
References:
J Am Soc Nephrol. 2001 Jun;12(6):1211-7. (PMID: 11373344)
Rev Endocr Metab Disord. 2010 Mar;11(1):61-74. (PMID: 20186491)
Circulation. 2000 Feb 15;101(6):676-81. (PMID: 10673261)
N Engl J Med. 2002 Jun 20;346(25):1999-2001. (PMID: 12075063)
J Hum Hypertens. 2017 Jun;31(6):395-399. (PMID: 28032631)
Hum Genet. 2001 Oct;109(4):408-15. (PMID: 11702222)
J Clin Invest. 1996 Jun 1;97(11):2601-10. (PMID: 8647954)
Science. 1996 Feb 2;271(5249):665-8. (PMID: 8571133)
Hypertension. 2001 Apr;37(4):1053-9. (PMID: 11304502)
High Blood Press Cardiovasc Prev. 2015 Dec;22(4):429-44. (PMID: 26403596)
Hypertension. 1998 Jan;31(1 Pt 2):409-14. (PMID: 9453337)
Eur Heart J. 2001 Dec;22(24):2243-52. (PMID: 11728144)
Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1142-7. (PMID: 15802620)
J Hypertens. 2008 Sep;26(9):1809-15. (PMID: 18698216)
Mol Endocrinol. 1997 Dec;11(13):1881-90. (PMID: 9415393)
Hypertension. 2000 Jul;36(1):103-9. (PMID: 10904020)
Hypertension. 2000 Jul;36(1):14-9. (PMID: 10904006)
Am J Hypertens. 2000 Dec;13(12):1308-14. (PMID: 11130776)
N Engl J Med. 1990 May 31;322(22):1561-6. (PMID: 2139921)
Circulation. 2007 Jul 3;116(1):85-97. (PMID: 17606856)
Int J Mol Sci. 2019 Mar 30;20(7):. (PMID: 30935055)
Diabetes. 2004 Oct;53(10):2645-52. (PMID: 15448096)
Circ Res. 2004 May 14;94(9):1211-8. (PMID: 15044323)
Hypertension. 2002 Dec;40(6):872-9. (PMID: 12468572)
PLoS One. 2014 Dec 02;9(12):e108872. (PMID: 25461385)
Hypertension. 1995 Aug;26(2):290-3. (PMID: 7635537)
J Clin Invest. 1998 Apr 15;101(8):1784-8. (PMID: 9541510)
Diabet Med. 1999 Mar;16(3):207-11. (PMID: 10227565)
Arterioscler Thromb Vasc Biol. 2007 May;27(5):1213-9. (PMID: 17347481)
Diabetol Metab Syndr. 2016 Nov 30;8:79. (PMID: 27956942)
Am J Med Sci. 2002 Sep;324(3):127-37. (PMID: 12240710)
Circulation. 2000 Jul 4;102(1):42-7. (PMID: 10880413)
Hypertension. 1999 Oct;34(4 Pt 2):724-8. (PMID: 10523349)
Curr Hypertens Rep. 2018 Feb 24;20(1):7. (PMID: 29478153)
Hypertension. 1997 Oct;30(4):859-67. (PMID: 9336385)
J Clin Endocrinol Metab. 1999 Jan;84(1):272-8. (PMID: 9920095)
N Engl J Med. 1999 Jan 14;340(2):115-26. (PMID: 9887164)
J Hypertens. 2014 Jan;32(1):166-73. (PMID: 24126712)
Circulation. 1999 Oct 26;100(17):1802-7. (PMID: 10534468)
J Cell Physiol. 2019 Nov;234(11):20217-20227. (PMID: 30989650)
Hypertension. 1994 Jan;23(1 Suppl):I12-5. (PMID: 8282343)
Curr Hypertens Rep. 2001 Feb;3(1):61-7. (PMID: 11177710)
Lancet. 2004 Jun 19;363(9426):2022-31. (PMID: 15207952)
Diabetes. 1996 Jul;45(7):881-5. (PMID: 8666137)
J Biol Chem. 1999 Aug 27;274(35):25078-84. (PMID: 10455187)
Endocrinology. 2000 Jun;141(6):1930-5. (PMID: 10830273)
Curr Cardiol Rep. 2020 Aug 8;22(10):105. (PMID: 32770420)
Cardiovasc Diabetol. 2019 Apr 30;18(1):56. (PMID: 31039789)
Diabetes Care. 2009 May;32(5):845-50. (PMID: 19223610)
BMC Cardiovasc Disord. 2012 Oct 15;12:89. (PMID: 23067205)
J Clin Invest. 2005 Aug;115(8):2128-38. (PMID: 16007268)
Circ Res. 2005 Feb 4;96(2):180-8. (PMID: 15591229)
Lancet. 2001 Mar 3;357(9257):686-7. (PMID: 11247555)
Am J Physiol Heart Circ Physiol. 2013 Apr 15;304(8):H1103-13. (PMID: 23396452)
High Blood Press Cardiovasc Prev. 2018 Sep;25(3):327-341. (PMID: 30232768)
Science. 1993 Jan 1;259(5091):87-91. (PMID: 7678183)
J Cardiovasc Transl Res. 2020 Jul 31;:. (PMID: 32737757)
J Hum Hypertens. 2010 Aug;24(8):519-24. (PMID: 20016524)
Endocrine. 2018 Dec;62(3):588-601. (PMID: 30101377)
N Engl J Med. 1996 Feb 8;334(6):374-81. (PMID: 8538710)
Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1597-602. (PMID: 15072967)
Am J Physiol. 1994 Feb;266(2 Pt 1):C319-34. (PMID: 8141246)
J Clin Endocrinol Metab. 2001 Mar;86(3):1154-9. (PMID: 11238501)
Nat Med. 2001 Oct;7(10):1138-43. (PMID: 11590438)
Curr Hypertens Rep. 2003 Oct;5(5):393-401. (PMID: 12948432)
Am J Hypertens. 2015 Jan;28(1):127-34. (PMID: 24936579)
Hypertension. 1999 Jul;34(1):113-7. (PMID: 10406833)
Trends Cardiovasc Med. 2006 Aug;16(6):183-8. (PMID: 16839860)
Cardiovasc Endocrinol Metab. 2019 Nov 13;8(4):96-105. (PMID: 31942550)
Eur Heart J. 2013 Nov;34(44):3419-26. (PMID: 23882068)
N Engl J Med. 1987 Aug 6;317(6):350-7. (PMID: 3299096)
BMJ. 2000 Jul 22;321(7255):199-204. (PMID: 10903648)
Int J Mol Sci. 2018 Sep 28;19(10):. (PMID: 30274207)
Mol Cell Biochem. 1998 May;182(1-2):91-9. (PMID: 9609118)
Am J Physiol Heart Circ Physiol. 2003 Apr;284(4):H1043-7. (PMID: 12666659)
JAMA. 2001 Oct 17;286(15):1882-5. (PMID: 11597291)
J Clin Invest. 1994 Dec;94(6):2511-5. (PMID: 7989610)
United European Gastroenterol J. 2018 Aug;6(7):1056-1064. (PMID: 30228894)
Hypertension. 2017 Jan;69(1):136-142. (PMID: 27895192)
J Clin Invest. 2000 May;105(9):1243-52. (PMID: 10791999)
Diabetes. 1973 Jul;22(7):507-13. (PMID: 4719190)
J Hypertens. 2001 Sep;19(9):1651-8. (PMID: 11564986)
J Clin Invest. 1992 Jul;90(1):24-9. (PMID: 1634611)
J Clin Invest. 1997 Jul 15;100(2):270-8. (PMID: 9218503)
Exp Clin Endocrinol Diabetes. 1999;107(2):119-25. (PMID: 10320052)
J Biol Chem. 1999 Dec 3;274(49):34795-802. (PMID: 10574950)
Eur Heart J. 2007 Dec;28(23):2937-43. (PMID: 17925342)
Circulation. 2001 Sep 11;104(11):1255-60. (PMID: 11551876)
Circulation. 1997 Sep 2;96(5):1432-7. (PMID: 9315528)
Circulation. 2013 Jan 1;127(1):86-95. (PMID: 23204109)
J Am Heart Assoc. 2016 Aug 20;5(8):. (PMID: 27543801)
J Hypertens. 2016 Apr;34(4):646-53. (PMID: 26895559)
Cardiovasc Diabetol. 2017 May 12;16(1):64. (PMID: 28499385)
Metabolism. 2015 Dec;64(12):1619-28. (PMID: 26481513)
Rev Med Liege. 2006 Oct;61(10):728-32. (PMID: 17209507)
Am J Hypertens. 2003 Nov;16(11 Pt 1):952-8. (PMID: 14573334)
Contributed Indexing:
Keywords: Atherosclerosis; Cardiovascular risk; Left ventricular hypertrophy; Microalbuminuria; Vascular inflammation
Substance Nomenclature:
0 (Biomarkers)
0 (Blood Glucose)
0 (Insulin)
Entry Date(s):
Date Created: 20200923 Date Completed: 20201124 Latest Revision: 20201124
Update Code:
20240105
PubMed Central ID:
PMC7661395
DOI:
10.1007/s40292-020-00408-8
PMID:
32964344
Czasopismo naukowe
Epidemiological studies have documented a high incidence of diabetes in hypertensive patients.Insulin resistance is defined as a less than expected biologic response to a given concentration of the hormone and plays a pivotal role in the pathogenesis of diabetes. However, over the last decades, it became evident that insulin resistance is not merely a metabolic abnormality, but is a complex and multifaceted syndrome that can also affect blood pressure homeostasis. The dysregulation of neuro-humoral and neuro-immune systems is involved in the pathophysiology of both insulin resistance and hypertension. These mechanisms induce a chronic low grade of inflammation that interferes with insulin signalling transduction. Molecular abnormalities associated with insulin resistance include the defects of insulin receptor structure, number, binding affinity, and/or signalling capacity. For instance, hyperglycaemia impairs insulin signalling through the generation of reactive oxygen species, which abrogate insulin-induced tyrosine autophosphorylation of the insulin receptor. Additional mechanisms have been described as responsible for the inhibition of insulin signalling, including proteasome-mediated degradation of insulin receptor substrate 1/2, phosphatase-mediated dephosphorylation and kinase-mediated serine/threonine phosphorylation of both insulin receptor and insulin receptor substrates. Insulin resistance plays a key role also in the pathogenesis and progression of hypertension-induced target organ damage, like left ventricular hypertrophy, atherosclerosis and chronic kidney disease. Altogether these abnormalities significantly contribute to the increase the risk of developing type 2 diabetes.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies